Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2 by Pellieux, C. et al.
Introduction
Cardiac hypertrophy represents an adaptive process of
the heart in response to work overload, and is common
in hypertensive individuals. The renin-angiotensin sys-
tem, through the activity of angiotensin II (Ang II), is
pivotal for blood pressure homeostasis, but can also
sustain high blood pressure in patients suffering from
hypertension (1). Besides its hemodynamic effects, Ang
II directly contributes to cardiac hypertrophy via its
growth factor properties (2, 3). Along this line, drugs
that inhibit Ang II production normalize blood pres-
sure and left ventricular hypertrophy (4). The trophic
actions of Ang II result in part from the release of fac-
tors with paracrine activities. One of these factors is
bFGF, also known as FGF-2 (5). For instance, car-
diomyocytes show a better response to Ang II in the
presence of cardiac fibroblasts, and this has been attrib-
uted to the presence of FGF-2 (6). Accordingly, Ang II
has been found to activate FGF-2 expression and release
from cardiac myocytes and fibroblasts (7, 8). FGF pro-
duction in the heart has been demonstrated (5), and has
been found to be upregulated after cardiac injury (9).
Recently, FGF-2 has been implicated in the hyper-
trophic response to pressure overload (10). In car-
diomyocytes, FGF induces phenotypic changes, includ-
ing the reexpression of genes encoding fetal isoforms of
contractile proteins (11, 12). However, the mechanisms
by which FGF could induce hypertrophy remains
unclear. FGF-2 lacks a signal sequence for secretion,
suggesting that it may be able to exit the cells only after
stretch, injury, or cell death (13, 14). Indeed, FGF-2 is
released by cardiomyocytes during contraction (13).
Moreover, various hypertrophic agonists other than
Ang II stimulate the release of FGF-2 (5, 7, 15).
FGF-2 binds to specific tyrosine kinase receptors,
leading to receptor dimerization, which enables the two
cytoplasmic domains to cross-phosphorylate each
other (5, 16). In cardiomyocytes, this receptor stimu-
lates phospholipase C, resulting in the production of
diacylglycerol and inositoltriphosphates, and activates
protein kinase C (16). In addition, FGF-2 activates Ras
and mitogen-activated protein kinases (MAPKs), name-
ly, the extracellular signal regulated kinases (ERKs), the
c-jun N-terminal kinases (JNKs), and the p38 kinase
(17). MAPKs have emerged as prominent players in the
development of cardiac hypertrophy (16, 17). However,
other pathways such as the calcium/calmodulin cal-
cineurin pathway could participate in establishing the
hypertrophic phenotype (18).
The two-kidney one-clip (2K1C) model of renovascu-
lar hypertension has greatly contributed to our under-
standing of hypertensive diseases (19). In this model,
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FGF-2 has been implicated in the cardiac response to hypertrophic stimuli. Angiotensin II (Ang II)
contributes to maintain elevated blood pressure in hypertensive individuals and exerts direct troph-
ic effects on cardiac cells. However, the role of FGF-2 in Ang II–induced cardiac hypertrophy has not
been established. Therefore, mice deficient in FGF-2 expression were studied using a model of 
Ang II–dependent hypertension and cardiac hypertrophy. Echocardiographic measurements show
the presence of dilated cardiomyopathy in normotensive mice lacking FGF-2. Moreover, hyperten-
sive mice without FGF-2 developed no compensatory cardiac hypertrophy. In wild-type mice, hyper-
trophy was associated with a stimulation of the c-Jun N-terminal kinase, the extracellular signal reg-
ulated kinase, and the p38 kinase pathways. In contrast, mitogen-activated protein kinase (MAPK)
activation was markedly attenuated in FGF-2–deficient mice. In vitro, FGF-2 of fibroblast origin was
demonstrated to be essential in the paracrine stimulation of MAPK activation in cardiomyocytes.
Indeed, fibroblasts lacking FGF-2 expression have a defective capacity for releasing growth factors to
induce hypertrophic responses in cardiomyocytes. Therefore, these results identify the cardiac fibrob-
last population as a primary integrator of hypertrophic stimuli in the heart, and suggest that FGF-2
is a crucial mediator of cardiac hypertrophy via autocrine/paracrine actions on cardiac cells.
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one renal artery is constricted to reduce renal perfu-
sion. This causes plasma renin and Ang II levels to
increase rapidly, leading to a chronic elevation of blood
pressure and to compensatory cardiac hypertrophy. We
recently created mice deficient in FGF-2 expression
using homologous recombination in embryonic stem
cells. Both high- and low-molecular-weight forms of
FGF-2 are lacking in these animals, which appear gross-
ly normal and not different from those described
recently by several other groups (10, 20–22). In this
study, we took advantage of a 2K1C murine model (23)
and of FGF-2 knockouts to investigate the role of 
FGF-2 in the development of cardiac hypertrophy.
Methods
Mice. Mice lacking FGF-2 gene expression (FGF-2–/–
mice) were generated using homologous recombina-
tion in embryonic stem cells by replacing most of the
second exon, resulting in the deletion of sequences
encoding amino acids 82–93 (A. Foletti and F. Beer-
mann, unpublished results). Depending on the strain,
mice carry either one or two renin genes (24). C57BL/6
mice are the prototype of one-renin-gene mice. There-
fore, to be more relevant to the human situation, mice
were backcrossed for five generations in a C57BL/6
background, and males bearing one renin gene were
used at 8 weeks of age.
2K1C hypertension. Briefly, mice were anesthetized
using 1.5% halothane in oxygen. The left kidney was
exposed, and a clip (0.12-mm opening) was placed on
the renal artery, which was isolated by blunt dissection
(23). The sham procedure included the entire surgery,
with the exception of artery clipping.
Blood pressure. Four weeks after clipping, the right
carotid artery was exposed, and a silicon catheter filled
with 5% glucose solution containing heparin (300
IU/ml) was inserted into the vessel and tunneled sub-
cutaneously to exit at the back of the neck. Blood pres-
sure was recorded in conscious mice by connecting the
catheter to a pressure transducer using a computerized
data acquisition system (Notocord Systems, Croissy-
sur-Seine, France).
Echocardiography. Left ventricular dimensions were
assessed 4–6 weeks after clipping in anesthetized mice
(90 mg/kg ketamine, 5 mg/kg xylazine, intraperitoneal)
by echocardiography using an ATL HDI 5000 ultra-
sound machine (Philips Medical Systems, Bothell,
Washington, USA) equipped with a 12-MHz phase
array linear transducer (L12-5). M-mode images were
used for measurement of wall thickness, chamber
dimension, and shortening fraction.
Cardiac weight index and cardiac protein homogenates. Car-
diac weight index was determined as the ratio of cardiac
ventricle weight to body weight. Ventricles were homog-
enized on ice in 1 ml RIPA buffer (150 mmol/l NaCl,
0.25% deoxycholic acid, 1% NP-40, 1 mmol/l NaVO3, 1
mmol/l NaF, 1 µg/ml aprotinin, 1 mmol/l PMSF, 1
µg/ml pepstatin A, 1 µg/ml leupeptin, 1 mmol/l EDTA,
and 50 mmol/l Tris, pH 7.5).
Histology. Heart sections from 2K1C wild-type
(FGF+/+) mice and FGF-2–/– mice were stained with
hematoxylin and eosin.
Plasma renin concentration. Plasma renin concentrations
were measured as described (23). Aliquots of plasma sam-
ples were incubated for 15 minutes at 37°C in the pres-
ence of plasma from nephrectomized rats as a source of
renin substrate. The Ang I concentrations produced dur-
ing the incubation period were determined with a sensi-
tive radioimmunoassay.
Northern blot analysis. Total RNA, purified from frozen
tissues using TriPure (Roche Diagnostics Corp., Basel,
Switzerland), was subjected to Northern blot analysis.
Ten micrograms of total RNA was separated on 1%
agarose-formaldehyde gel, transferred to GeneScreen
nylon membrane (NEN Life Science Products Inc.,
Boston, Massachusetts, USA), and hybridized with
radiolabeled cDNA probes spanning the mouse renin
(kidney RNA) and atrial natriuretic factor (cardiac
RNA) sequences. Signals were quantified using an
Instant Imager (Packard Bioscience Co., Meriden, Con-
necticut, USA), and normalized to the GAPDH signal.
Cell culture. Neonatal ventricles were digested at 37°C
in 116 mmol/l NaCl, 1 mmol/l NaH2PO4, 5.4 mmol/l
KCl, 0.8 mmol/l MgSO4⋅7H2O, 5.5 mmol/l glucose,
and 20 mmol/l HEPES (pH 7.4) containing 0.45 mg/ml
collagenase (Worthington Biochemical Corp., Lake-
wood, New Jersey, USA) and 1 mg/ml pancreatin (Life
Technologies Inc., San Diego, California, USA). Cells
were washed by centrifugation in a 3:1 mixture of
DMEM and Medium 199 (Life Technologies Inc.) sup-
plemented with 10% horse serum (Serotec Ltd., Oxford,
United Kingdom), 5% FBS (Serotec Ltd.), 2 mmol/l L-
glutamine (Life Technologies Inc.), 10 mg/ml strepto-
mycin, and 100 UI/ml penicillin (Life Technologies
Inc.). Cardiomyocytes and nonmyocyte cells (NMCs)
were separated by differential plating (45 minutes), and
plated at a density of 1 × 105 cells/cm2 on gelatin-coat-
ed wells and noncoated wells, respectively. After 24
hours, cardiomyocytes were switched to serum-free
medium. NMCs were passaged once before switching
to serum-free medium. Cells were stimulated with Ang
II, FGF-2, or NMC supernatants, washed with PBS, and
lysed in 2× SDS-PAGE loading buffer.
Production of conditioned medium from NMC culture.
NMCs were grown to subconfluence in 10-cm dishes,
placed in serum-free medium for 24 hours, and stimu-
lated for 24 hours with 100 nM Ang II. FGF-2 concentra-
tions in supernatants were measured by ELISA (Chemi-
con International Inc., Temecula, California, USA).
MAPK activation. Thirty micrograms of soluble protein
was run in a 10% SDS-PAGE gel and transferred onto
nitrocellulose (ECL nitrocellulose; Amersham Pharma-
cia Biotech Ltd., Little Chalfont, United Kingdom).
Phosphorylation of MAPK was determined by incuba-
tion with specific antibodies for the phosphorylated and
nonphosphorylated forms of p38, ERK, and JNK (New
England Biolabs, Beverly, Massachusetts, USA) at 4°C in
blotto (20 mmol/l Tris, pH 7.6, containing 0.1% Tween-
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20 and 5% dry milk). Primary antibodies were revealed
with anti-rabbit secondary antibodies conjugated to
horseradish peroxidase, using a chemiluminescent detec-
tion system (Amersham Pharmacia Biotech Ltd.).
Immunofluorescence. Sarcomeres in cardiomyocytes
(fixed with 3% paraformaldehyde) were detected using
a monoclonal anti–myomesin B4 antibody kindly
provided by Jean-Claude Perriard (Swiss Institute of
Technology, Zurich, Switzerland) (25), and a confocal
unit equipped with an inverted microscope (LSM 410;
Carl Zeiss, Jena, Germany).
Protein synthesis. Protein synthesis was determined
by adding [3H]phenylalanine (5 µCi/ml) to culture
medium, and counting uptake using standard scin-
tillation techniques.
Expression of α-skeletal actin. Protein was detected by
Western blot analysis using an anti–α-skeletal actin
polyclonal antiserum as described (26).
Statistical analysis. Data are expressed as mean ± SEM.
Statistical analysis was performed using the Student-
Newman-Keuls test. P values less than 0.05 were con-
sidered significant.
Results
Dilated cardiomyopathy and absence of hypertrophic responses
in FGF-2–deficient mice. Using echocardiography, cardiac
dimensions and functions were evaluated in mice lack-
ing FGF-2 under basal conditions, or in an Ang
II–dependent model of renovascular hypertension and
cardiac hypertrophy (the 2K1C model) (Tables 1 and 2).
Left ventricular wall thickness was not different between
sham-operated FGF-2+/+ and FGF-2–/– mice. However,
FGF-2–/– mice had enlarged left chambers, as shown by
the increased diastolic and systolic diameters, and expe-
rienced cardiac dysfunction, as shown by the smaller
shortening fraction (Table 2). The absence of FGF-2 led
to a slight (and not significant) decrease in blood pres-
sure compared with wild-type mice (Table 1). However,
both FGF-2+/+ and FGF-2–/– animals demonstrated a sig-
nificant and similar elevation of blood pressure 4 weeks
after clipping. Accordingly, renin expression in the kid-
neys was significantly stimulated in both hypertensive
groups (ratio of kidney renin to GAPDH: 68 ± 8 vs. 149
± 9 in sham-operated and 2K1C FGF-2+/+ mice, and 
68 ± 4 vs. 127 ± 7 in sham-operated and 2K1C FGF-2–/–
mice, respectively; P < 0.05). Moreover, circulating renin
concentrations were similar in both clipped groups
(plasma renin concentrations: 1602 ± 272 ng Ang I/ml/h
vs. 1224 ± 163 ng Ang I/ml/h in 2K1C FGF-2+/+ mice and
FGF-2–/– mice, respectively; no significant difference). We
then investigated the role of FGF-2 in the development
of cardiac hypertrophy in this model. Hypertensive 
FGF-2+/+ mice showed a marked increase in cardiac mass
(Table 1). Cardiac hypertrophy in response to chronic
hypertension was also evident in FGF-2+/+ mice by
echocardiography, as shown by the increase in wall thick-
ness (Table 2). In contrast, hypertensive FGF-2–/– mice
showed no cardiac hypertrophic response, as demon-
strated by the inability of the heart to increase its mass
(Table 1), the absence of a compensatory increase in wall
thickness, and no improvement of cardiac dilation
(Table 2). The absence of compensatory hypertrophy in
hypertensive FGF-2 knockouts is also evident from his-
tological sections of left ventricular myocytes (Figure 1).
Furthermore, cardiac performance in hypertensive 
FGF-2–/– mice, as assessed by the measurement of the
shortening fraction, never reached that seen in controls
(Table 2). In agreement with this observation, atrial
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Table 1
Cardiac parameters in normotensive and hypertensive FGF-2+/+ and FGF-2–/– mice
Group Age Genotype n BW MBP HW CWI ANF/GAPDH
(weeks) (g) (mmHg) (mg) (mg/g) ratio
Sham 12 FGF-2+/+ 15 25.7 ± 0.7 118 ± 2** 109 ± 3* 4.24 ± 0.07* 92 ± 7*
FGF-2–/– 17 24.9 ± 1.1 112 ± 3** 100 ± 5* 3.99 ± 0.09* 80 ± 3*
2K1C 12 FGF-2+/+ 13 26.8 ± 0.5 143 ± 3** 124 ± 3* 4.62 ± 0.09* 117 ± 11*
FGF-2–/– 17 26.2 ± 0.7 131 ± 2*† 109 ± 4† 4.16 ± 0.08† 87 ± 5†
BW, body weight; MBP, mean blood pressure; HW, heart weight; CWI, cardiac weight index; ANF, atrial natriuretic factor. *P < 0.05 compared with sham-
operated animals. †P < 0.05 compared with 2K1C FGF-2+/+ mice.
Table 2
Echocardiographic parameters in normotensive and hypertensive FGF-2+/+ and FGF-2–deficient mice
Group Genotype n LVDD LVDS LVWTD LVWTS SWTD SWTS SF
(cm) (cm) (cm) (cm) (cm) (cm) (%)
Sham FGF-2+/+ 8 0.31 ± 0.03* 0.19 ± 0.03* 0.10 ± 0.01** 0.12 ± 0.02* 0.09 ± 0.02* 0.11 ± 0.02* 39 ± 2*
FGF-2–/– 8 0.39 ± 0.01† 0.29 ± 0.03† 0.09 ± 0.02** 0.11 ± 0.02* 0.06 ± 0.02* 0.09 ± 0.02* 26 ± 4†
2K1C FGF-2+/+ 9 0.28 ± 0.02* 0.17 ± 0.02* 0.14 ± 0.02** 0.16 ± 0.03* 0.11 ± 0.02 0.14 ± 0.03* 42 ± 2*
FGF-2–/– 9 0.41 ± 0.02† 0.30 ± 0.03† 0.07 ± 0.01† 0.10 ± 0.02† 0.06 ± 0.01† 0.08 ± 0.01† 27 ± 2†
LVDD, left ventricular diameter, end-diastole; LVDS, left ventricular diameter, end-systole; LVWTD, left ventricular wall thickness, end-diastole; LVWTS, left
ventricular wall thickness, end-systole; SWTD, septal wall thickness, end-diastole; SWTS, septal wall thickness, end-systole; SF, shortening fraction. *P < 0.05
compared with sham-operated mice. †P < 0.05 compared with FGF-2+/+ mice.
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natriuretic factor expression in the hearts of hyperten-
sive FGF-2–/– mice was not activated (Table 1).
Reduced cardiac MAPK activation in the hearts of hyper-
tensive FGF-2–deficient mice. Activation of MAPK has
been associated with the development of cardiac hyper-
trophy induced by growth factors and hemodynamic
changes. To determine the role of FGF-2 in MAPK acti-
vation during the development of cardiac hypertrophy,
phosphorylation of JNK, ERK, and p38 was studied in
2K1C mice. All three kinases are activated in the hyper-
trophied hearts of hypertensive FGF-2+/+ controls (Fig-
ure 2). In contrast, stimulation of JNK and ERK was
reduced in 2K1C FGF-2–/– mice. Although slightly
reduced, activation of p38 was not significantly dimin-
ished in this series of experiments.
Direct MAPK activation by Ang II or FGF-2 in cardiomy-
ocytes is not affected by FGF-2 deficiency. To determine
whether the lack of FGF-2 could play a role in the direct
stimulation of cardiomyocytes by Ang II or FGF-2, we
studied MAPK activation in cardiac myocytes in vitro.
Ang II was readily able to activate JNK, ERK, and p38
in cardiomyocytes from either FGF-2+/+ mice or 
FGF-2–/– mice (Figure 3). Similarly, added FGF-2
induced MAPK activation in cardiomyocytes regardless
of the capacity of the cells to produced FGF-2.
FGF-2 and FGF-2–dependent trophic factors from NMCs
mediate Ang II–induced hypertrophic responses in cardiomy-
ocytes. Since FGF-2+/+ and FGF-2–/– cardiomyocytes
appeared to respond normally to Ang II and FGF-2, we
investigated possible paracrine stimulation of cardiomy-
ocytes by factors from NMCs. Interestingly, in wild-type
cells, FGF-2 seemed to be produced mainly by NMCs
(Table 3). Moreover, FGF-2 secretion appeared to be fur-
ther stimulated by Ang II. The absence of FGF-2 in super-
natants from FGF-2–/– cardiomyocytes and NMCs was
also confirmed (Table 3). Next, conditioned supernatants
from NMC cultures were assayed for their capacity to
stimulate MAPK in cardiomyocytes (Figure 4). Phospho-
rylation of JNK, ERK, and p38 was stimulated in FGF-2+/+
cardiomyocytes by supernatants from FGF-2+/+ NMC
cultures. The stimulatory activity of FGF-2+/+ NMC
supernatants was greatly enhanced when NMCs were
stimulated with Ang II. Furthermore, costimulation of
FGF-2+/+ cardiomyocytes by FGF-2+/+ NMC supernatants
and Ang II produced maximal activation of the MAPK
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Figure 1
Defective cardiac hypertrophic response to Ang II–dependent reno-
vascular hypertension in FGF-2–/– mice. Histological sections of hearts
from equally hypertensive FGF-2+/+ (a) and FGF-2–/– (b) mice 4 weeks
after clipping. See Table 1 for details of the parameters in 2K1C mice.
Figure 2
MAPK activation in the hearts of normotensive sham-operated (sham) or hypertensive 2K1C mice (a). Phosphorylation of JNK, ERK, and p38
was detected using specific antibodies (b). Data were quantified by laser scanning densitometry after Western blotting. Results represent fold
activation compared with sham-operated FGF-2+/+ controls. Values are expressed as mean ± SEM (n = 5–10). *P < 0.05 compared with sham-
operated FGF-2+/+ mice. †P < 0.05. NS, not significant.
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pathways. In sharp contrast, the stimulatory activity of
supernatants from FGF-2–/– NMC cultures was greatly
reduced, but not completely abolished.
To further investigate the role of FGF-2 in the
paracrine activation of cardiomyocytes, supernatants
from wild-type cultures were tested for their capacity to
stimulate MAPK in FGF-2+/+ cardiomyocytes in the
absence or presence of neutralizing anti–FGF-2 anti-
bodies (Figure 4). Interestingly, the blocking of FGF-2
activity only partially abolished the ability of FGF-2+/+
NMC supernatants to activate MAPK. Moreover, the
capacity of supernatants from cultures containing
anti–FGF-2 antibodies to stimulate MAPK was reduced
to a lesser extent than that of supernatants from cul-
tures of FGF-2–/– NMCs. This is particularly evident in
the case of the JNK pathway.
To exclude a possible inability of FGF-2–/– cardiomy-
ocytes to respond normally to factors from NMCs, we
first determined the capacity of cardiac myocytes from
FGF-2 knockouts to show a hypertrophic response in
the presence of conditioned medium from Ang II–stim-
ulated wild-type NMC culture. As shown in Figure 5,
supernatants from FGF-2+/+ NMCs triggered hypertro-
phy similarly in cardiomyocytes from FGF-2+/+ and
FGF-2–/– mice, as assessed by measuring the increases
in protein synthesis, cell surface area, and sarcomere
organization. In contrast, data in Figure 6 demonstrate
the reduced capacity of supernatants from NMCs to
induce a hypertrophic response in wild-type cardiomy-
ocytes. This inability to induce morphological changes
in cardiomyocytes by supernatants from NMCs lacking
FGF-2 was also confirmed by the lack of α-skeletal
actin expression in myocytes (Figure 6).
Discussion
The pathways leading to compensatory cardiac hyper-
trophy remain poorly understood. In the present study,
we took advantage of a physiological model of reno-
vascular hypertension to study the role of FGF-2 in the
development of Ang II–dependent cardiac hypertrophy.
Mice deficient for FGF-2 expression demonstrated
dilated cardiomyopathy, and failed to increase their
cardiac mass in response to an elevation of blood pres-
sure. In addition, MAPK activation in the hearts of
FGF-2–deficient mice also appeared to be reduced. This
defective MAPK activation results in part from the
absence of paracrine stimulation of cardiomyocytes by
growth factors from Ang II–stimulated cardiac NMCs
— an absence that prevents cardiomyocytes from initi-
ating morphological adaptation to stress.
The FGF family contains about twenty members,
which bind to four distinct receptor tyrosine kinases
(5). Despite the fact that most FGFs bind to all recep-
tors, each FGF appears to display specific effects. In
particular, FGF-2 mediates various biological
responses, including mitogenesis and differentiation.
FGF-2 is expressed in the heart, and its expression is
upregulated by hemodynamic load (13, 14). It has
been shown to activate MAPK pathways (17), and to
play a direct role in the hypertrophic response of car-
diomyocytes (27, 28). Indeed, the MAPK stimulatory
activity of supernatants from fibroblast cultures was
significantly attenuated by anti–FGF-2 neutralizing
antibodies (Figure 4), suggesting that part of the activ-
ity is due to the presence of FGF-2 in these super-
natants. This is equally demonstrated by the large
decrease in the capacity of supernatants from FGF-2–/–
fibroblasts to stimulate MAPK (Figure 4). This is in
accordance with results showing that pericardial fluid
has trophic effects on adult cardiomyocytes, mainly
due to high FGF-2 concentrations (28). However, our
study also shows that other growth factors are likely
to be involved. Indeed, supernatants from FGF-2–/–
cultures retained some capacity to stimulate MAPK in
cardiomyocytes, and anti–FGF-2 antibodies, although
in great excess, do not completely abolish the stimu-
latory activity of culture supernatants (Figure 4).
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Figure 3
Normal MAPK activation by Ang II and FGF-2 in
primary cardiomyocytes. Cardiomyocytes from
either FGF-2+/+ or FGF-2–/– mice were stimulated
by either 100 nM Ang II or 20 nM FGF-2 for 10
minutes (JNK) or 5 minutes (ERK and p38).
Phosphorylation of JNK, ERK, and p38 was
detected using specific antibodies. Data were
quantified by laser scanning densitometry.
Results represent fold activation compared with
unstimulated FGF-2+/+ cardiomyocytes. Values
are expressed as mean ± SEM (n = 3). *P < 0.05
compared with unstimulated FGF-2+/+ car-
diomyocytes. NS, not significant.
Table 3
FGF-2 concentrations (ng/ml) in supernatants from unstimulated or
Ang II–stimulated cardiomyocyte (CM) and NMC cultures
CM NMC
FGF-2+/+ FGF-2–/– FGF-2+/+ FGF-2–/–
No Ang II **0 ± 0.2** 0 ± 0.6 **9 ± 0.9* 0 ± 0.5
100 nM Ang II 2.9 ± 0.3* 0 ± 0.4 18.5 ± 0.7* 0 ± 0.3
*P < 0.05 compared with culture medium.
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI13627
1848 The Journal of Clinical Investigation | December 2001 | Volume 108 | Number 12
Figure 4
MAPK activation in primary cardiomyocytes by NMC culture supernatant. FGF-2+/+ cardiomyocytes were unstimulated, or stimulated by 100
nM Ang II (gray bar), by supernatants (SN) from either unstimulated (white bars) or Ang II–stimulated NMC cultures (black bars), and by
a combination of NMC SN and Ang II. Treatment was for 10 minutes for JNK (a) and 5 minutes for ERK (b) and p38 (c). Anti–FGF-2 Ab
indicates addition of neutralizing antibodies to FGF-2. (d and e) Phosphorylation of JNK, ERK, and p38 was detected using specific anti-
bodies. Lanes 1 and 9: unstimulated control; lanes 2 and 10: 100 nM Ang II; lanes 3–8: supernatants from unstimulated NMCs; lanes 11–16:
supernatants from Ang II–stimulated NMCs. Lanes 3–6 and 11–14: supernatants from FGF-2+/+ NMCs; lanes 7, 8, 15, and 16: supernatants
from FGF-2–/– NMCs; lanes 5, 6, 8, 13, 14, and 16: 100 nM Ang II present; lanes 4, 6, 12, and 14: anti–FGF-2 antibodies present. Data were
quantified by laser scanning densitometry. Results represent fold activation compared with unstimulated control. Values are expressed as
mean ± SEM (n = 3). *P < 0.05 compared with unstimulated control. †P < 0.05.
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Moreover, particularly in the case of JNK, the capaci-
ty of supernatants to stimulate MAPK after neutral-
ization of FGF-2 activity was greater than that of
supernatants from FGF-2–/– cultures. This suggests
that the release of some factors is dependent on the
ability of fibroblasts to secrete FGF-2.
Our results demonstrate that Ang II stimulates
fibroblasts to produce growth factors. Several studies
implicate Ang II in cardiac fibrosis due to stimulated
fibroblast proliferation (29). Ang II also has direct
growth-promoting effects on cardiomyocytes (2, 3).
However, these effects could result in part from
paracrine actions of growth factors from Ang II–stim-
ulated fibroblasts. Indeed, inhibition of fibroblast
proliferation in cultures of neonatal cardiac cells
reduces Ang II–induced protein synthesis in car-
diomyocytes (30). Furthermore, a recent study
demonstrated the importance of AT-1–receptor
expressing cardiomyocytes in the proliferative
response of cardiac fibroblasts to Ang II (31). Indeed,
Ang II, via AT-1 receptors, appears to upregulate 
FGF-2 expression in cardiac myocytes (7). FGF-2 itself
increases FGF-2 transcription levels. Interestingly,
culture supernatants from Ang II–activated cardiac
fibroblasts stimulate protein synthesis in cardiomy-
ocytes (6, 32) (Figure 5). The activity of the super-
natants is not blocked by antibodies directed against
FGF-1 or FGF-2, but is significantly attenuated by the
addition of neutralizing antibodies to TGF-β (32).
The results presented herein demonstrate the impor-
tance of FGF-2 in the stimulation of cardiomyocytes
and in the release of other trophic factors by fibrob-
lasts, and also the existence of extensive crosstalk
between cardiac myocytes and fibroblasts that is cru-
cial for the hypertrophic response.
Mice deficient in FGF-2 expression appear to suffer
from dilated cardiomyopathy (Tables 1 and 2). Since
cardiac dilation is already present in normotensive ani-
mals, it suggests that FGF-2 could play an important
role in maintaining cardiac integrity. Recently, several
groups independently generated mice that were defi-
cient in FGF-2 expression (10, 20–22). Dilated car-
diomyopathy in mice lacking FGF-2 has not been
reported. The reason for this discrepancy is currently
The Journal of Clinical Investigation | December 2001 | Volume 108 | Number 12 1849
Figure 5
Normal hypertrophic response of FGF-2+/+ and FGF-2–/– cardiomyocytes to supernatants from Ang II–stimulated FGF-2+/+ NMCs. Cardiomyocytes
from either FGF-2+/+ or FGF-2–/– mice were stimulated with supernatants from FGF-2+/+ Ang II–stimulated NMC cultures. Protein synthesis was
evaluated by [3H]phenylalanine incorporation (a). Fixed cells were stained with antibodies to myomesin B4, analyzed by confocal microscopy (d),
and cell surface area (b) and number of cells with organized sarcomeres (c) were determined. *P < 0.05 compared with unstimulated control.
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not known. In the animals used in the present study,
most of the second FGF-2 exon was replaced, and RT-
PCR analysis showed a total absence of FGF-2 expres-
sion (A. Foletti and F. Beermann, unpublished results).
Similarly, FGF-2 message containing exon 2 has not
been observed in earlier studies (21), therefore making
it unlikely that some truncated forms of FGF-2
account for the different phenotype. Alternatively, the
genetic background in which the animals are main-
tained could play a role. For instance, our mice were
backcrossed in a one-renin-gene strain (24), whereas
the mixed background of 129 and Black Swiss mice
used in the previous studies carry two renin genes. In
addition, one cannot exclude the possibility that dis-
tinct intracellular pathways are activated in response to
pressure overload and Ang II–induced high blood pres-
sure. In particular, we have recently demonstrated
crosstalk between the MAPK, protein kinase C, and cal-
cineurin pathways in the Ang II–mediated hyper-
trophic response in renovascular hypertension (33).
Hypertensive animals lacking FGF-2 do not develop
cardiac hypertrophy. Consistently, atrial natriuretic
factor is not upregulated in the
hearts of FGF-2–/– mice (Table 1).
The absence of a hypertrophic
response to chronic hypertension
appears to result in part from a
deficient production of growth
factors from Ang II–activated car-
diac fibroblasts. Indeed, cardiomy-
ocytes fail to develop hypertrophy
in vitro in response to super-
natants from FGF-2–/– fibroblast
cultures (Figure 6). In particular,
α-skeletal actin expression is not
activated. FGF-2–deficient ani-
mals were previously shown to
develop significantly less hyper-
trophy and reduced fibrosis in
response to pressure overload (10).
In this aortic coarctation model,
the renin-angiotensin system is
not activated, and plasma Ang II
levels remain low. Thus, Ang
II–induced stimulation of FGF-2
secretion probably did not play a
major role. Indeed, pressure over-
load can induce cardiac hypertro-
phy in mice lacking AT-1A recep-
tors (34). Therefore, it is likely that
hemodynamic overload represents
the prime stimulator of FGF-2
release in this particular case,
whereas in renovascular hyperten-
sion, both Ang II and Ang II–medi-
ated increases in mechanical stress
induce FGF-2 secretion from car-
diac cells. FGF-2 lacks a signal
sequence for secretion (5), and
could exit the cells following stretch or injury. Mice
lacking FGF-2 were shown to display some reduction
in blood pressure but a normal blood pressure
response to Ang II (20, 21). In the present study, 
FGF-2 knockouts are characterized by a nonsignifi-
cant reduction in blood pressure at basal conditions
(Table 1). In addition, the elevation of blood pressure
in the Ang II–dependent model of renovascular hyper-
tension was not different from that seen in wild-type
mice. This confirms a normal blood pressure response
to Ang II in FGF-2 knockouts. On the other hand, 
Ang II directly contributes to hypertrophy (2, 3).
Indeed, experiments in vitro demonstrated the capac-
ity of Ang II to stimulate fibroblasts independently of
hemodynamic stress. Our results suggest that various
stimuli can activate fibroblasts in the heart. Thus, we
propose that the cardiac fibroblast population may
represent a primary integrator of biomechanical stress.
Its activation would lead to growth factor secretion,
and thereby to the induction of compensatory pheno-
types in cardiomyocytes, provided that the hyper-
trophic stimulus is able to trigger FGF-2 release.
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Figure 6
Deficient capacity of supernatants from FGF-2–/– NMCs to induce hypertrophic responses
in FGF-2+/+ cardiomyocytes. FGF-2+/+ cardiomyocytes were stimulated with supernatants
from either FGF-2+/+ NMC cultures (black bars) or FGF-2–/– NMC cultures (white bars),
stained with antibodies to myomesin B4, and studied by confocal microscopy. Cell surface
area (a) and number of cells exhibiting organized sarcomeres (b) were determined. Expres-
sion of α-skeletal actin was measured by Western blot analysis (c and d). *P < 0.05 com-
pared with the unstimulated control. †P < 0.05.
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